Moreover, the objective response rate of the combined therapy was more obvious in LGG compared to patients with BRAF V600E mutated HGG (ORR of 26%) [45].These studies reminded us that if there were enough controlled studies available for analysis in the future, the efficacy of the combined therapy versus (VS) single drug in LGG, including how soon to start responding and how long a response sustains, or the efficacy of the combined therapy in low-grade VS high-grade gliomas should be focused on. The gene discussed is BRAF; the disease is glioma.